Circular Genomics launches Alzheimer's blood test with advanced predictive capability

On July 2, 2026, Circular Genomics announced the launch of its CircPATH platform, introducing a blood-based diagnostic tool capable of predicting Alzheimer's disease symptoms years before they manifest. The release follows a study published in Nature Medicine, which demonstrated that circular RNA biomarkers can map the preclinical progression of the neurodegenerative disease with a high degree of accuracy.

The medical application of this blood test marks a specific, measurable shift in neurodegenerative diagnostics. Until recently, the clinical standard has relied on biomarkers such as pTau217 to detect Alzheimer's pathology. According to the foundational research behind CircPATH, the newly utilized circular RNA (circRNA) biomarkers offer a 61 percent stronger predictive power for the progression to symptomatic Alzheimer's disease than pTau217 alone.

This improvement in predictive accuracy allows for precise risk stratification at a stage previously inaccessible to routine, non-invasive screening. By identifying multi-pathway disease biology directly from a blood sample, clinicians are now equipped to isolate the biological indicators of Alzheimer's years in advance. This extended predictive window substantially alters the timeline upon which medical professionals can assess, monitor, and categorize high-risk patient populations.

The clinical reliance on blood-based circRNA testing moves the diagnostic timeline backward while broadening the scope of what a single draw can capture. Rather than measuring an isolated protein indicator, the CircPATH methodology reads multiple biological pathways associated with the disease's early development. This provides a comprehensive molecular baseline for patients well before the earliest signs of cognitive decline begin to present clinically.

The introduction of this diagnostic platform directly addresses a longstanding limitation in Alzheimer's care: the extensive gap between biological onset and symptomatic visibility. By securing a reliable forecast years ahead of clinical symptoms, the medical sector now possesses the biological framework required to evaluate and respond to the disease in its earliest, asymptomatic stages.